^
BIOMARKER:
EGFR amplification
i
Other names: EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Entrez ID:
EGFR amplification
NSCLC
gefitinib
Sensitive
:
B
EGFR amplification
SCCHN
afatinib
Sensitive
:
B
EGFR amplification
NSCLC
erlotinib
Sensitive
:
C2
EGFR amplification
GBM
ABT-414
Sensitive
:
C2
EGFR amplification
GBM
lapatinib
Sensitive
:
C2
EGFR amplification
Esophageal Squamous Cell Carcinoma
afatinib
Sensitive
:
C2
EGFR amplification
GBM
KD019
Sensitive
:
C2
EGFR amplification
SCCHN
Immunotherapy
Resistant
:
C3
EGFR amplification
Gastric Cancer
cetuximab
Sensitive
:
C3
EGFR amplification
GBM
erlotinib
Resistant
:
C3
EGFR amplification
Melanoma
Immunotherapy
Resistant
:
C3
EGFR amplification
Mucosal Melanoma
ipilimumab
Resistant
:
C3
EGFR amplification
Mucosal Melanoma
nivolumab
Resistant
:
C3
EGFR amplification
Mucosal Melanoma
nivolumab + ipilimumab
Resistant
:
C3
EGFR amplification
Mucosal Melanoma
pembrolizumab
Resistant
:
C3
EGFR amplification
CRC
cetuximab
Resistant
:
C3
EGFR amplification
CRC
panitumumab
Sensitive
:
C3
EGFR amplification
NSCLC
osimertinib
Resistant
:
C3
EGFR amplification
Solid Tumor
ABSK-091
Sensitive
:
C3
EGFR amplification
Lung Cancer
gefitinib
Resistant
:
C3
EGFR amplification
Lung Cancer
icotinib
Resistant
:
C3
EGFR amplification
NSCLC
bevacizumab + erlotinib
Sensitive
:
C3
EGFR amplification
NSCLC
bevacizumab + gefitinib
Sensitive
:
C3
EGFR amplification
LUAD
afatinib
Sensitive
:
C4
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our